Work

A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-111951

Authors: Ehab L. Atallah, Johnnie J. Orozco, Michael Craig, Moshe Yair Levy, Laura E. Finn, Sharif S. Khan, Alexander E. Perl, Jae H. Park, Gail J. Roboz, William Tse, Kebede H. Begna, Raya Mawad, David A. Rizzieri, Mark S. Berger, Joseph G. Jurcic

Institutions: Medical College of Wisconsin, Fred Hutch Cancer Center, West Virginia University, Baylor University Medical Center, Ochsner Medical Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine, University of Louisville, Mayo Clinic, Duke University, Duke Medical Center, Actinium Pharmaceuticals (United States), Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2914051390

Cites:

Cited by: 16

Related to: 10